As there is a tumour agnostic oncological treatment for cancer patients with an NTRK fusion, we would like to propose that one should screen for this gene rearrangement in CRC patients with dMLH1/BRAFV600Ewt/MLH1ph using Idylla gene fusion test or pan-TRK IHC, followed by an RNA–based NGS confirmation of the positive cases, or alternatively using upfront RNA–based NGS depending on local resources. Here, NTRK1 is linked to cancer.